Abstract
Doxorubicin (DXR), administered iv in rats at the weekly dose of 3 mg/kg for 5 weeks, significantly impaired body weight gain and induced irreversible ECG alterations, mainly consisting of a progressive prolongation of ST and QT intervals. Five weeks after the last DXR administration, the contractile performance of atria isolated from treated animals was significantly reduced. At the same time, relevant morphologic lesions, consisting of myocyte vacuolization and myofibrillar loss, were also present in the myocardium of the same rats. The study showed that ICRF-187, administered ip at a dose of 125 mg/kg, significantly prevented body weight loss. QT and ST prolongation, and the decreased contractile force induced by DXR. In addition, ICRF-187 caused a significant reduction in incidence and severity of myocardial lesions. The cardioprotective effect of ICRF-187 is not mediated by a modification in DXR pharmacokinetics in heart, since the drug was actually found to increase DXR uptake in myocardial cells.
References
Nov 1, 1989·Investigational New Drugs
Mar 1, 1985·Biochemical Pharmacology·P J Thornalley, N J Dodd
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·E H Herman, V J Ferrans
May 1, 1988·Pharmacological Research Communications·E MontiF Villani
Apr 1, 1985·Toxicology and Applied Pharmacology·E H HermanB Ardalan
Nov 1, 1980·Journal of Cardiovascular Pharmacology·G BuschmannU G Kühl
Feb 28, 1984·Biochemistry·H EliotC Myers
Apr 13, 1982·Biochemistry·C E MyersR Greene
Sep 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P M MayD R Williams
Citations
Jan 1, 1992·Cancer Chemotherapy and Pharmacology·C AgenM Del Tacca
Jan 1, 1992·Cancer Chemotherapy and Pharmacology·T K YeungJ W Hopewell
Dec 23, 2008·Breast Cancer Research and Treatment·Joseph Gligorov, Jean-Pierre Lotz
Apr 4, 2008·Cell Biology and Toxicology·Vilma A SardãoKendall B Wallace
Jan 1, 1996·Free Radical Biology & Medicine·E MontiC Oliva
Mar 14, 2001·European Journal of Pharmacology·E L De BeerE E Voest
Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R T DorrS McLean
May 2, 2009·Toxicological Sciences : an Official Journal of the Society of Toxicology·Mehdi S HazariAimen K Farraj
Aug 26, 2000·British Journal of Pharmacology·B E BurkeB J Cusack
Mar 15, 2016·Canadian Journal of Physiology and Pharmacology·Hussein F SakrAyman Z Elsamanoudy
Oct 15, 2011·Journal of Applied Toxicology : JAT·Seref AlpsoyAsuman Gedikbasi
Jan 1, 1993·Cancer Treatment Reviews·R L Basser, M D Green
Mar 13, 2001·Toxicology and Applied Pharmacology·T ZimaV R Preedy
Oct 22, 2016·Advanced Pharmaceutical Bulletin·Nasser RazmaraiiYadollah Azarmi
Jan 1, 1992·Critical Reviews in Toxicology·T P Ryan, S D Aust
Jul 1, 1996·Toxicologic Pathology·P Della TorreG Mazué
Jan 17, 2002·Toxicologic Pathology·T ZimaV R Preedy
Oct 26, 2013·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·O M DisliH Parlakpinar
Jun 25, 2013·The Journal of Pharmacology and Experimental Therapeutics·Mina Mhallem GziriFrédéric Amant
Jun 17, 2011·The Cochrane Database of Systematic Reviews·Elvira C van DalenLeontien Cm Kremer
Sep 26, 2013·Human & Experimental Toxicology·R UygurO A Ozen
Sep 1, 1994·The Annals of Pharmacotherapy·C F SeifertD F Thompson
Aug 2, 2018·Molecular Medicine Reports·Rong WuJian-Ping Gao
Jun 5, 2021·Nutrition and Cancer·Mahboobeh Ghasemzadeh RahbardarHossein Hosseinzadeh
Nov 9, 2007·Toxicology·Roohollah Babaei KelishomiAhmad Reza Dehpour